Page last updated: 2024-10-30

lansoprazole and Asthma

lansoprazole has been researched along with Asthma in 19 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).

Research Excerpts

ExcerptRelevanceReference
"Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)."9.20Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015)
"To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER."9.16Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012)
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo."9.11Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005)
"The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score."6.72A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006)
"Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)."5.20Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015)
"Respiratory adverse events from a clinical trial of lansoprazole in children with asthma were analyzed for associations with extensive or poor metabolizer (PM) phenotype based on CYP2C19 haplotypes."5.17Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children. ( Blake, KB; Gong, Y; Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wise, RA, 2013)
"We analyzed 306 children between 6 and 17 years of age with poorly controlled asthma enrolled in a 6-month trial assessing lansoprazole for asthma control."5.17Obesity in children with poorly controlled asthma: Sex differences. ( Dixon, AE; Holbrook, JT; Irvin, CG; Lang, JE; Lima, JJ; Shade, D; Teague, WG; Wei, CY; Wise, RA, 2013)
"To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER."5.16Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012)
"Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo."5.11Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005)
" The Genotype Tailored Treatment of Symptomatic Acid Reflux in Children with Uncontrolled Asthma (GenARA) study is a randomized, double-blind, placebo-controlled trial to determine if genotype-tailored PPI dosing improves asthma symptoms among children with inadequately controlled asthma and GERD symptoms."2.90Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. ( Blake, KV; Cobbaert, M; Fischer, BM; Franciosi, J; Hossain, MJ; Lang, JE; Lima, JJ; Mougey, EB; Schmidt, S; Tang, M, 2019)
"The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score."2.72A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006)
"Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress."1.34Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. ( Dobashi, K; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Ono, A; Shimizu, Y; Utsugi, M; Yanagitani, N; Zhao, JJ, 2007)
"Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown."1.33Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006)
"The causal association between gastro-oesophageal reflux disease (GERD) and difficult-to-control asthma is unclear."1.33Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (47.37)29.6817
2010's9 (47.37)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Wang, WT1
Li, CY1
Chang, YT1
Bai, YM1
Tsai, SJ1
Chen, TJ1
Chiou, SH1
Chen, MH1
Tang, M1
Blake, KV1
Lima, JJ6
Mougey, EB3
Franciosi, J1
Schmidt, S1
Hossain, MJ1
Cobbaert, M1
Fischer, BM1
Lang, JE5
Blake, KB1
Gong, Y1
Holbrook, JT5
Wise, RA4
Teague, WG4
Pierog, AA1
Mencin, AA1
Wei, CY2
Sukhovershin, RA1
Ghebremariam, YT1
Cooke, JP1
Arand, M1
Gold, BD1
Blake, K1
Brown, ED1
Castro, M1
Dozor, AJ1
Mastronarde, JG1
Sockrider, MM1
Martinez, FD1
Dixon, AE1
Irvin, CG1
Shade, D1
Yüksel, H1
Yilmaz, O1
Kirmaz, C1
Aydoğdu, S1
Kasirga, E1
Littner, MR1
Leung, FW1
Ballard, ED1
Huang, B1
Samra, NK1
Katz, PO1
Wong, CH2
Chua, CJ1
Liam, CK1
Goh, KL2
Shimizu, Y2
Dobashi, K2
Kobayashi, S1
Ohki, I1
Tokushima, M1
Kusano, M1
Kawamura, O1
Shimoyama, Y1
Utsugi, M2
Sunaga, N1
Ishizuka, T2
Mori, M2
Sato, A1
Tanifuji, Y1
Kobayashi, H1
Inoue, H1
Zhao, JJ1
Kawata, T1
Ono, A1
Yanagitani, N1
Kaira, K1
Hisada, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013]Phase 4306 participants (Actual)Interventional2007-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Airways Reactivity (Assessed by Methacholine PC20)

Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24

Interventionmg/mL (Mean)
Lansoprazole Group2.6
Placebo Group2.5

Asthma Symptom Utility Index (ASUI)

ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24

Interventionscore (Mean)
Lansoprazole Group0.86
Placebo Group0.88

Asthma-specific Quality of Life

Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24

Interventionscore (Mean)
Lansoprazole Group5.8
Placebo Group6.0

Change in Juniper Asthma Control Score (ACS)

Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24

Interventionscore (Mean)
Lansoprazole Group1.1
Placebo Group1.0

Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24

InterventionLiters (Mean)
Lansoprazole Group2.2
Placebo Group2.3

Rate of Episodes of Poor Asthma Control (EPAC)

"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary

Interventionnumber of episodes of poor asthma contrl (Number)
Lansoprazole Group230
Placebo Group184

Reviews

1 review available for lansoprazole and Asthma

ArticleYear
Gastroesophageal reflux disease and extraesophageal disease.
    Reviews in gastroenterological disorders, 2005, Volume: 5 Suppl 2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo

2005

Trials

7 trials available for lansoprazole and Asthma

ArticleYear
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
    Contemporary clinical trials, 2019, Volume: 78

    Topics: Adolescent; Asthma; Body Weights and Measures; Child; Cytochrome P-450 CYP2C19; Double-Blind Method;

2019
Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.
    The Journal of pediatrics, 2013, Volume: 163, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Asthma; Bronchit

2013
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
    Annals of the American Thoracic Society, 2015, Volume: 12, Issue:6

    Topics: Adolescent; Asthma; Child; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Gastroesophageal Reflu

2015
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
    JAMA, 2012, Jan-25, Volume: 307, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adolescent; Adrenal Cortex Horm

2012
Obesity in children with poorly controlled asthma: Sex differences.
    Pediatric pulmonology, 2013, Volume: 48, Issue:9

    Topics: Adolescent; Asthma; Body Mass Index; Child; Cohort Studies; Female; Forced Expiratory Volume; Humans

2013
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
    Chest, 2005, Volume: 128, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult;

2005
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
    The Tohoku journal of experimental medicine, 2006, Volume: 209, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation;

2006

Other Studies

11 other studies available for lansoprazole and Asthma

ArticleYear
Proton-pump inhibitors are associated with an increased risk of asthma: A nationwide nested case-control study.
    Allergy and asthma proceedings, 2023, 09-01, Volume: 44, Issue:5

    Topics: Asthma; Case-Control Studies; Esomeprazole; Female; Humans; Lansoprazole; Male; Proton Pump Inhibito

2023
A childhood case of eosinophilic gastritis and protein-losing enteropathy.
    Clinical pediatrics, 2014, Volume: 53, Issue:3

    Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Asthma; Child, Preschool; Cromol

2014
Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved?
    Annals of the American Thoracic Society, 2015, Volume: 12, Issue:7

    Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra

2015
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
    Annals of the American Thoracic Society, 2015, Volume: 12, Issue:7

    Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra

2015
[Nocturnal shortness of breath: in asthma look for reflux -- is it worthwhile?].
    MMW Fortschritte der Medizin, 2008, Dec-11, Volume: 150, Issue:51-52

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Bronchodilator Agents; Gastroesophageal Reflux; Hum

2008
Children, asthma, and proton pump inhibitors: costs and perils of therapeutic creep.
    JAMA, 2012, Jan-25, Volume: 307, Issue:4

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Enzyme Inhibitors; Female; Humans; Lansoprazole; Ma

2012
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
    Respiratory medicine, 2006, Volume: 100, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch

2006
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
    Alimentary pharmacology & therapeutics, 2006, May-01, Volume: 23, Issue:9

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory

2006
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
    Arerugi = [Allergy], 2006, Volume: 55, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux;

2006
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:15

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans;

2006
Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
    Respiration; international review of thoracic diseases, 2007, Volume: 74, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Biomarkers; Breath Tests; Comorbidity; Dinoprost; F

2007